A Study of GensSci098 in Subjects With Graves' Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorChangchun GeneScience Pharmaceutical Co., Ltd.
About this trial
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Voluntary signed informed consent.
Confirmed diagnosis of diffuse toxic goiter (Graves' disease).
Abnormal thyroid function tests (e.g., elevated T4, and suppressed TSH).
Disqualifiers
Non-diffuse toxic goiter-induced hyperthyroidism.
Previous radioactive iodine treatment or thyroid surgery.
History or risk of thyroid storm.
Use of thyroid hormone medications within the past 6 weeks.
Trial design
Treatments tested in this trial
- GenSci098
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov